LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Închisă

SectorSănătate

14.43 0.14

Rezumat

Modificarea prețului

24h

Curent

Minim

14.23

Maxim

14.45

Indicatori cheie

By Trading Economics

Venit

1.5B

14B

Vânzări

3.4B

84B

P/E

Medie Sector

18.329

56.602

EPS

19.11

Randament dividend

0.71

Marjă de profit

16.795

EBITDA

2.4B

24B

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.71%

2.45%

Statistici piață

By TradingEconomics

Capitalizare de piață

9.3B

12B

Deschiderea anterioară

14.29

Închiderea anterioară

14.43

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2024, 13:33 UTC

Achiziții, Fuziuni, Preluări

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million -- Update

26 iun. 2024, 12:32 UTC

Achiziții, Fuziuni, Preluări

Haleon to Sell Nicotine-Quitting Aid Business for $634 Million

9 mai 2025, 18:56 UTC

Câștiguri

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 mai 2025, 18:56 UTC

Câștiguri

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

23 ian. 2025, 17:46 UTC

Câștiguri

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 ian. 2025, 17:42 UTC

Câștiguri

Dr. Reddy's 3Q Rev INR83.59B

5 nov. 2024, 11:01 UTC

Câștiguri

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov. 2024, 11:00 UTC

Câștiguri

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov. 2024, 10:57 UTC

Câștiguri

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov. 2024, 10:57 UTC

Câștiguri

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

26 iun. 2024, 11:54 UTC

Achiziții, Fuziuni, Preluări

Haleon: All Other 2024 Guidance Unchanged

26 iun. 2024, 11:54 UTC

Achiziții, Fuziuni, Preluări

Haleon: Sale Will Dilute 2024 Rev by 0.5%, Adj Oper Pft by 1%

26 iun. 2024, 11:52 UTC

Achiziții, Fuziuni, Preluări

Haleon: Sale Allow For NRT Exit Outside US, Trims Business Complexity

26 iun. 2024, 11:51 UTC

Achiziții, Fuziuni, Preluări

Haleon: Deal Expected to Complete Early 4Q

26 iun. 2024, 11:50 UTC

Achiziții, Fuziuni, Preluări

Haleon: Use of Proceeds Will Be in Line With Capital Allocation Priorities

26 iun. 2024, 11:49 UTC

Achiziții, Fuziuni, Preluări

Haleon: Deal Structure Upfront Cash GBP458M, GBP42M Performance-Based Payable

26 iun. 2024, 11:48 UTC

Achiziții, Fuziuni, Preluări

Haleon: Portfolio Includes Nicotinell, Nicabate, Habitrol and Thrive Available in Gum, Lozenge

26 iun. 2024, 11:47 UTC

Achiziții, Fuziuni, Preluări

Haleon: Deal Worth GBP500M With Additional Proceeds From Inventory Transfer

26 iun. 2024, 11:46 UTC

Achiziții, Fuziuni, Preluări

Haleon to Sell Non-US Nicotine Replacement Therapy Business to Dr. Reddy's Laboratories

Comparație

Modificare preț

Dr Reddy's Laboratories Ltd-ADR Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

N/A / 13.84Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Weak Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.